Spinal Muscular Atrophy (SMA): Complete Treatment Description

Background

Classification by Type

Disease-Modifying Therapies (SMN-Enhancing)

1. Nusinersen (Spinraza)

• Class: Antisense oligonucleotide (ASO)
• Mechanism: Modifies pre-mRNA splicing of the SMN2 gene, promoting inclusion of exon 7 and increased production of full-length SMN protein
• Route: Intrathecal (lumbar puncture)
• Dosing: 4 loading doses (12 mg each) over 2 months, then maintenance every 4 months
• Approval: US FDA 2016; EMA 2017
• Indications: All SMA types; approved for all ages
• Evidence: ENDEAR trial (infantile-onset) and CHERISH trial (later-onset) showed significant motor improvement vs. sham control (NEJM 2017; NEJM 2018)
• Adverse effects (infantile-onset): Lower respiratory infection, constipation. Later-onset: fever, headache, vomiting, back pain (post-lumbar puncture syndrome)
• Notable 2024-25 update: The DEVOTE trial tested a higher dose (50 mg loading, 28 mg maintenance) showing superior efficacy vs. standard 12 mg dose in infantile-onset SMA

2. Onasemnogene Abeparvovec (Zolgensma)

• Class: Gene replacement therapy (one-time treatment)
• Mechanism: AAV9 vector delivers a functional copy of SMN1 DNA; establishes an episome with its own promoter, restoring SMN protein production
• Route: Single IV infusion
• Dosing: Single dose: 1.1 × 10¹⁴ vector genomes/kg
• Approval: US FDA 2019 (age <2 years); EMA 2020
• Indications: Patients <2 years of age (US), or up to 21 kg (EMA); best results when given pre-symptomatically or in early Type 1
• Contraindications/Precautions: Anti-AAV9 antibodies (seropositivity may preclude therapy); required concomitant corticosteroids to manage hepatotoxicity risk
• Adverse effects: Elevated liver aminotransferases, vomiting; requires liver function monitoring
• Drug interactions: Vaccination schedule must be adjusted to accommodate concurrent corticosteroid administration

3. Risdiplam (Evrysdi)

• Class: Small molecule SMN2 splicing modifier
• Mechanism: Similar to nusinersen - promotes exon 7 inclusion in SMN2 pre-mRNA, increasing full-length SMN protein levels; acts systemically (penetrates CNS via oral route)
• Route: Oral (liquid formulation)
• Dosing: Once daily; weight-based dosing
• Approval: US FDA 2020; EMA 2021
• Indications: All SMA types; approved from birth onward; particularly useful when intrathecal access is difficult
• Evidence: FIREFISH (Type 1 infants) and SUNFISH (Types 2/3) trials showed significant motor function improvement
• Adverse effects: Fever, diarrhea, rash; may increase plasma concentrations of drugs eliminated via MATE (multidrug and toxin extrusion) protein transporters
• Advantage: Non-invasive oral route; suitable for home administration

Comparison Summary

Treatment Selection Principles

• Treat as soon as possible - delay reduces the magnitude of benefit
• Any of the three approved agents may be used; decision based on patient/family factors, AAV9 antibody status, and access

1. First-line: Onasemnogene abeparvovec if clinically stable, no advanced disease, anti-AAV9 antibody negative
2. Consider risdiplam if gene therapy is contraindicated or non-invasive route preferred
3. Nusinersen as alternative when gene therapy or oral route not feasible

• Nusinersen or risdiplam are preferred (onasemnogene is approved only for younger patients in the US)
• Higher baseline function and earlier initiation correlate with better outcomes

• Real-world data are emerging on combining agents (e.g., risdiplam or nusinersen after onasemnogene); not yet standard of care but being explored in clinical trials (2025 systematic review, PMID 40879810)

Supportive/Multidisciplinary Care

• Passive and active physical therapy to maintain range of motion
• Lightweight orthotics/braces

• Pulmonary function monitoring
• Non-invasive ventilatory support (BiPAP/CPAP) - leading cause of death in untreated Type 1 is respiratory failure
• Cough assist devices (mechanical insufflation-exsufflation)
• Tracheostomy in severe cases

• Swallowing assessment; gastrostomy feeding if aspiration risk
• Nutritional monitoring given reduced mobility

• Scoliosis monitoring and surgical correction when needed (spinal fusion)
• Growing rod techniques for young children with severe SMA and progressive scoliosis
• Fracture prevention (reduced bone density from immobility)

Prognosis with Treatment

• All three therapies improve motor function for up to 48 months of follow-up
• Better outcomes with earlier treatment initiation and higher baseline function
• Motor improvements are consistent across SMA types
• Respiratory and nutritional outcomes show less improvement than motor function - underscoring the continued importance of multidisciplinary supportive care
• Long-term efficacy, optimal therapy duration, and potential for motor regression remain active research questions

Key Recent Evidence (2024-2025)